Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
Revenue (Most Recent Fiscal Year) | $124.79M |
Net Income (Most Recent Fiscal Year) | $4.35B |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 69.97 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.59 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | 3713.24% |
Net Margin (Trailing 12 Months) | 3827.42% |
Return on Equity (Trailing 12 Months) | -14.65% |
Return on Assets (Trailing 12 Months) | -13.19% |
Current Ratio (Most Recent Fiscal Quarter) | 10.43 |
Quick Ratio (Most Recent Fiscal Quarter) | 10.43 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $7.99 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.37 |
Earnings per Share (Most Recent Fiscal Year) | $-1.15 |
Diluted Earnings per Share (Trailing 12 Months) | $5.65 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 727.95M |
Free Float | 670.44M |
Market Capitalization | $8.79B |
Average Volume (Last 20 Days) | 4.44M |
Beta (Past 60 Months) | 1.27 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 7.90% |
Percentage Held By Institutions (Latest 13F Reports) | 64.76% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |